NCT04182880已完成2 期
Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain After Mini-abdominoplasty Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Mean (Peak) Plasma Concentration (Cmax)
研究概览
简要总结
Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in patients after mini-abdominoplasty
详细描述
This is a randomized, double-blind, study to evaluate the safety, PK profile of CPL-01 for the management of postoperative pain after mini-abdominoplasty surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject provides signed, written informed consent before participation in the study.
- •Subject is aged ≥18 and ≤70 years at the time of informed consent and is male or female.
- •Subject is scheduled to undergo elective mini-abdominoplasty surgery under general anesthesia without collateral procedures.
- •Female subjects are eligible only if all the following apply:
- •Not pregnant
- •Not breastfeeding
- •Not planning to become pregnant during participation in the study
- •Committed to the use of an acceptable form of birth control for the duration of the study until at least 30 days after administration of IP.
- •Male subjects must commit to the use of a reliable method of birth control for the duration of the study until at least 30 days after administration of IP or be surgically sterile (biologically or surgically).
- •Subject is free of any physical, mental, or medical conditions which, in the opinion of the investigator, make mini-abdominoplasty or study participation inadvisable.
排除标准
- •Subject has known, suspected, or reported history of alcohol or drug abuse or dependence within the previous 2 years as assessed by the investigator
- •Subject has impaired liver function (e.g., aspartate aminotransferase/alanine aminotransferase greater than 3 times the upper limit of the reference range, bilirubin greater than 1.5 times the upper limit of the reference range unless due to Gilbert's syndrome, active hepatic disease, evidence of clinically significant liver disease, or other condition such as alcoholism, cirrhosis, or hepatitis, etc.) that suggests the potential for an increased susceptibility to hepatic toxicity with IP exposure.
- •Subject has clinically significant renal abnormalities (creatinine ≥1.5 × upper limit of normal).
- •Subject has hemoglobin A1c ≥7.0%.
- •Subject has participated in another clinical study and/or received an IP (marketed or premarket) within 30 days before surgery.
- •Subject has a history of, or positive test results for, human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody at Screening.
- •Subject with an upper respiratory infection/cough in the 14 days before surgery.
- •Subjects with a history of significant postoperative nausea and vomiting.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
CPL-01
Experimental
CPL-01
干预措施: CPL-01 (Drug)
结局指标
主要结局
Mean (Peak) Plasma Concentration (Cmax)
时间窗: Baseline through 120 hours after start of study drug administration
Mean Cmax of 573 ng/mL and occurred at approximately 13 hours. Timepoints tested included before study drug administration and 15, 30, and 45 minutes and 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, 48, 60, 72, 96, and 120 hours after administration.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)Celiac DiseaseNCT05574010Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA128
已完成
1 期
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid WithdrawalOpioid WithdrawalNCT04470050BioXcel Therapeutics Inc225
招募中
2 期
Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 DiabetesType 2 DiabetesNCT05248776Celon Pharma SA80
已完成
2 期
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off ReversalParkinson's DiseaseNCT03541356Impel Pharmaceuticals32
终止
1 期
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB SubjectsChronic Hepatitis BNCT05001022Aligos Therapeutics40